Dansket

Is anyone using this combination? Is the Mobilab label format different that the Meditech label format? Does phlebotomist return with labeled tubes or free labels and labeled tubes?

Have done DAT's cord blood sample in gel (manual and automated) for more than 15 years without washing. Stopped washing cord blood samples routinely prior to tube testing in the 80's.

I do love my ProVues! VISION was designed starting with a blank sheet. I was given a powerpoint presentation and was impressed with this new instrument that uses the same gel cards as ProVue. Within a 12-18 months after release, expect vialed antisera for antigen typing on VISION. VISION retrieves the gel cards needed for testing from the cartons that are stored within the instrument. Reagent Red Blood Cells can be stored on-board for 5 days. These two features will decrease the learning curve for generalists accustomed to operating core lab instruments with on-board reagents. VISION can run selected panel cells!! VISION(400 lbs)is slightly larger and twice as heavy as ProVue (200 lbs.). Vision ProVue Width: 42.3 in. 40.0 in. Depth: 30.31 in. 24.0 in. Height:35 in. 25.59 Height with maintenance door open: 54 in. 36.5 in. Just a note: Be sure to ask your ORTHO representative about an ORTHO product RESOLVIGEN that is currently available in Europe, but not in the US. This product should be integrated into VISION for as an aid to antibody identification, i.e. printing a report of antigen rule-outs based on reactivity of patient plasma with panel cells.

It is my post in the Library

I use a single profile test that contains two resultable tests for immediate-spin and anti-IgG crossmatches. If patient qualifies for electronic crossmatch, Meditech 'NP's both tests and interprets the crossmatch as compatible. If patient does not qualify for electronic crossmatch, both tests are available for serological test result entry. I've never used the 'replace XM test' function.

Cliff, I can't edit file I uploaded by clicking one "Edit File". Please advise

It is a suggestion, not a requirement.

I think this practice (collecting cord blood into a lavender top and a red top)goes back 3-4 decades. The lavender top could be used for hematology and the red top for chemistry. In my previous facility, we stopped collecting cord blood period. Specimens were collected by venipuncture or heel stick. After hemology was done, we used that same specimen to screen for HDF/N. In my current facility, cord blood is routinely collected by Nursing into lavender and red tops. We toss the lavendar top and use the red top (after removing the large clot) on ProVue to screen for HDF/N. Totally misread. Have never collected a red top for immune-resetting test, only an EDTA tube.

I would discard the entire inventory. Then I would wonder if there was an alarm activation. If not, why not? If alarm was activated, was action taken or was it ignored? Do you have a backup freezer?

Most of the male Rh negative patients who developed anti-D in our facility only received apheresis platelets, no other blood components.

nisar10281: As I re-read this: anti-A not detected in patient plasma by Innova glass bead or by standard tube in 1st blood sample. Two additional blood samples collected: anti-A is detected in patient plasma by which method, Innova or Tube?

Cliff, When I log into the library and select my upload, the text "Edit" is displayed. When I click on it, nothing happens. Please advise how I can edit my file

This is not that rare in ORTHO Gel. In 0.8% of 3500 adult plasma specimens tested from group O, A and B patients, expected anti-A and/or anti-B was not detected in the ABO Plasma Grouping test. One of thefundamental differences between column agglutination technology and standard test tube is the use of centrifugation. In column-agglutination, centrifugation is used to separate agglutinated rbcs from unagglutinated rbcs. In standard tube, centrifugation is used to enhance the antigen-antibody reaction. So some IgM antibodies may not react as well in 'columns' as they do in tube. I reported this in 1997 at the AABB meeting in Denver. Our standard approach is to repeat the ABO Plasma Grouping test in test tube. This resolves 80% of the discrepancies.

Have been using ORTHO BioCLone Anti-D antiserum in both manual gel (1996) and in ProVue (2005) for Weak D testing on newborn blood samples (presented data for Weak D testing in manual gel at 1997 AABB annual meeting in Denver).

We report "Compatible". I've not used the term "presumed compatible" before.

For Gel users, the FDA has stated that a crossmatch done with an Anti-IgG Gel card cannot be used to demonstrate ABO compatibility, that an immediate-spin (gel or tube) must be done in addition to the IgG crossmatch. When ORTHO submitted the Anti-IgG Gel card to the FDA, the submission did not include data for the detection of ABO incompatiblity. Several papers have been reported at the AABB Annual Meeting that provide some evidence that the IgG gel card does detect ABO incompatiblity. I see some similarities between this and your situation. Just got off the phone with ORTHO Technical Services and they confirmed that legally IgG gel card may not be used to detect ABO incompatible by crossmatch.

I consider all of the following to be different methods: manual tube, manual gel,PEG, enzyme, solid-phase, ProVue, Galileo, Echo, Tango, Immune Rosetting Test kits, Kleihauer-Betke Staining kits.

Are you using a Blood Bank computer system? If so, it could be configured to interpret weak reactivity with anti-D. Does your antisera's manufacturer direction insert address this issue? After you have done all this then I would echo Malcolm's post. Standardization is the key to resolving these types of issues and controversies.

Please do. Thanks

Cell #4 of ORTHO PANEL C lot# VRC203 is listed as Ror (D+C-c+E-e+). With all deference to Malcolm, do you consider Ror to have a single or double dose of the D antigen? I think D is present in a single dose on an Ror cell and that panel cell is "heterozygous" for the D antigen. Panel cells that are R1R1 or R2R2 are double dose or homozygous for the D antigen. Am I correct? I don't think anti-D should be ruled out if cell# 4 is non-reactive but all other D positive cells are weakly-agglutinated (1+) and all D negative cells are not agglutinated.

I've been using 2 ProVues the past 6 years. We don't experience constant mechanical breakdowns.

Computer crossmatch.

Have always considered Rh Immune Globlulin Prophylaxis one of the many services provided by Transfusion Services.

Yes, not clinically significant.